Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Matching Empagliflozin	242
Overall Study	STARTED	Empagliflozin 2.5 Milligram (mg)	242
Overall Study	STARTED	Empagliflozin 10 mg	248
Overall Study	STARTED	Empagliflozin 25 mg	245
Overall Study	Treated	Placebo Matching Empagliflozin	241
Overall Study	Treated	Empagliflozin 2.5 Milligram (mg)	241
Overall Study	Treated	Empagliflozin 10 mg	248
Overall Study	Treated	Empagliflozin 25 mg	245
Overall Study	COMPLETED	Placebo Matching Empagliflozin	224
Overall Study	COMPLETED	Empagliflozin 2.5 Milligram (mg)	232
Overall Study	COMPLETED	Empagliflozin 10 mg	235
Overall Study	COMPLETED	Empagliflozin 25 mg	233
Overall Study	NOT COMPLETED	Placebo Matching Empagliflozin	18
Overall Study	NOT COMPLETED	Empagliflozin 2.5 Milligram (mg)	10
Overall Study	NOT COMPLETED	Empagliflozin 10 mg	13
Overall Study	NOT COMPLETED	Empagliflozin 25 mg	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02580591/flow